Published in J Immunol on July 27, 2011
Why must T cells be cross-reactive? Nat Rev Immunol (2012) 1.88
Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides. Eur J Immunol (2014) 1.49
Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. J Biol Chem (2011) 1.37
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A (2013) 1.14
Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity. Nat Immunol (2015) 1.03
Cutting edge: Evidence for a dynamically driven T cell signaling mechanism. J Immunol (2012) 1.03
Reconciling views on T cell receptor germline bias for MHC. Trends Immunol (2012) 0.98
Computational design of the affinity and specificity of a therapeutic T cell receptor. PLoS Comput Biol (2014) 0.96
TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility. J Immunol (2014) 0.94
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
Targeting human melanoma neoantigens by T cell receptor gene therapy. J Clin Invest (2016) 0.92
Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J Clin Invest (2016) 0.90
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Sci Rep (2012) 0.90
The basis for limited specificity and MHC restriction in a T cell receptor interface. Nat Commun (2013) 0.90
Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition. J Biol Chem (2013) 0.89
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother (2012) 0.88
Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front Immunol (2013) 0.88
How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire. Proc Natl Acad Sci U S A (2016) 0.88
Disparate epitopes mediating protective heterologous immunity to unrelated viruses share peptide-MHC structural features recognized by cross-reactive T cells. J Immunol (2013) 0.86
Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol (2012) 0.85
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J Mol Biol (2013) 0.83
Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop. Nat Commun (2013) 0.83
Specific increase in potency via structure-based design of a TCR. J Immunol (2014) 0.82
Structure of Staphylococcal Enterotoxin E in Complex with TCR Defines the Role of TCR Loop Positioning in Superantigen Recognition. PLoS One (2015) 0.82
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol (2015) 0.82
Changing the peptide specificity of a human T-cell receptor by directed evolution. Nat Commun (2014) 0.80
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells. J Virol (2014) 0.79
Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell. Exp Biol Med (Maywood) (2015) 0.79
Effect of CDR3 sequences and distal V gene residues in regulating TCR-MHC contacts and ligand specificity. J Immunol (2014) 0.78
Crystal structure of the N-myristoylated lipopeptide-bound MHC class I complex. Nat Commun (2016) 0.78
A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces. Protein Eng Des Sel (2016) 0.78
Differential utilization of binding loop flexibility in T cell receptor ligand selection and cross-reactivity. Sci Rep (2016) 0.78
T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron (2013) 0.77
An Engineered Switch in T Cell Receptor Specificity Leads to an Unusual but Functional Binding Geometry. Structure (2016) 0.77
Soluble T-cell receptors produced in human cells for targeted delivery. PLoS One (2015) 0.76
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol (2016) 0.76
Comparing domain interactions within antibody Fabs with kappa and lambda light chains. MAbs (2016) 0.75
CD8 T-cell responses against the immunodominant Theileria parva peptide Tp249-59 are composed of two distinct populations specific for overlapping 11-mer and 10-mer epitopes. Immunology (2016) 0.75
Lipopeptides: a novel antigen repertoire presented by major histocompatibility complex class I molecules. Immunology (2016) 0.75
A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen. J Biol Chem (2016) 0.75
MHC Bias by T Cell Receptors: Genetic Evidence for MHC and TCR Coevolution. Trends Immunol (2016) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
Inference of macromolecular assemblies from crystalline state. J Mol Biol (2007) 44.95
XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. J Struct Biol (1999) 17.84
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Shape complementarity at protein/protein interfaces. J Mol Biol (1993) 10.40
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature (1996) 6.20
wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models. Acta Crystallogr D Biol Crystallogr (1997) 5.58
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today (1998) 5.07
How a single T cell receptor recognizes both self and foreign MHC. Cell (2007) 3.20
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol (2006) 3.15
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 2.97
Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol (2008) 2.79
Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat Immunol (2007) 2.78
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol (2007) 2.55
Homology modeling, model and software evaluation: three related resources. Bioinformatics (1998) 2.47
T cell allorecognition via molecular mimicry. Immunity (2009) 2.25
TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol (2002) 2.12
T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med (2004) 1.99
In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A (2000) 1.92
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 1.85
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol (2001) 1.77
Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes. Biochem J (2008) 1.56
Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. J Mol Biol (2005) 1.55
T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity (2009) 1.55
Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem (2009) 1.51
Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr Opin Immunol (2009) 1.42
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol (2007) 1.36
Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem (2004) 1.29
T cell receptor recognition via cooperative conformational plasticity. J Mol Biol (2006) 1.28
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol (2009) 1.20
Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins (2009) 1.16
Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer (1999) 1.16
Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics. J Immunol (2011) 1.10
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 1.09
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol (2002) 1.07
Specificity on a knife-edge: the alphabeta T cell receptor. Curr Opin Struct Biol (2006) 1.03
Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants. J Mol Biol (2005) 1.03
Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition. J Biol Chem (2004) 0.99
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother (2010) 0.92
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol (2007) 0.92
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol (2010) 0.90
Methods for quantifying T cell receptor binding affinities and thermodynamics. Methods Enzymol (2009) 0.84
MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing. Eur J Immunol (2007) 0.79
Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes. Biochem J (2008) 1.56
Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. J Mol Biol (2005) 1.55
T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity (2009) 1.55
Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. J Biol Chem (2011) 1.37
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol (2007) 1.36
Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities. J Mol Recognit (2008) 1.34
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30
Interactions between CLIP-170, tubulin, and microtubules: implications for the mechanism of Clip-170 plus-end tracking behavior. Mol Biol Cell (2005) 1.29
T cell receptor recognition via cooperative conformational plasticity. J Mol Biol (2006) 1.28
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol (2005) 1.27
Thermodynamic and kinetic analysis of a peptide-class I MHC interaction highlights the noncovalent nature and conformational dynamics of the class I heterotrimer. Biochemistry (2003) 1.16
Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics. J Immunol (2011) 1.10
Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation. Biochemistry (2004) 1.07
A comprehensive calorimetric investigation of an entropically driven T cell receptor-peptide/major histocompatibility complex interaction. Biophys J (2007) 1.04
Disparate degrees of hypervariable loop flexibility control T-cell receptor cross-reactivity, specificity, and binding mechanism. J Mol Biol (2011) 1.03
Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants. J Mol Biol (2005) 1.03
Cutting edge: Evidence for a dynamically driven T cell signaling mechanism. J Immunol (2012) 1.03
Fluorine substitutions in an antigenic peptide selectively modulate T-cell receptor binding in a minimally perturbing manner. Biochem J (2009) 1.00
Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition. J Biol Chem (2004) 0.99
Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol Immunol (2009) 0.99
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Eng Des Sel (2010) 0.98
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem (2012) 0.96
Lysine Nzeta-decarboxylation switch and activation of the beta-lactam sensor domain of BlaR1 protein of methicillin-resistant Staphylococcus aureus. J Biol Chem (2011) 0.96
TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility. J Immunol (2014) 0.94
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
The basis for limited specificity and MHC restriction in a T cell receptor interface. Nat Commun (2013) 0.90
Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition. J Biol Chem (2013) 0.89
MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors. J Immunol (2002) 0.89
T cell receptor binding transition states and recognition of peptide/MHC. Biochemistry (2007) 0.89
Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front Immunol (2013) 0.88
Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics. Mol Immunol (2010) 0.86
An amino acid position at crossroads of evolution of protein function: antibiotic sensor domain of BlaR1 protein from Staphylococcus aureus versus clasS D β-lactamases. J Biol Chem (2012) 0.84
Methods for quantifying T cell receptor binding affinities and thermodynamics. Methods Enzymol (2009) 0.84
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J Mol Biol (2013) 0.83
Limitations of time-resolved fluorescence suggested by molecular simulations: assessing the dynamics of T cell receptor binding loops. Biophys J (2012) 0.81
Kinetics of thermal unfolding of phenylalanine hydroxylase variants containing different metal cofactors (FeII, CoII, and ZnII) and their isokinetic relationship. Inorg Chem (2008) 0.78
Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition. J Med Chem (2010) 0.75
A general and efficient approach for NMR studies of peptide dynamics in class I MHC peptide binding grooves. Biochemistry (2009) 0.75
Design, synthesis and evaluation of β-lactam antigenic peptide hybrids; unusual opening of the β-lactam ring in acidic media. Org Biomol Chem (2010) 0.75